A Phase 4 interventional study of Adalimumab and Methotrexate in Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 49 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-18.
Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 29th largest by enrollment, is one of 4 that started in 2010, is one of 33 in phase 4, and was the 37th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 309 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
This study is registered under AbbVie (prior sponsor, Abbott), one of the names counted as AbbVie. Under that name alone:
AbbVie (prior sponsor, Abbott) is the lead sponsor of 223 studies on the registry; none are open to participants now.
80 studies in Arthritis, Rheumatoid by AbbVie: 5 open now, 6 under way, 1 of them phase 3. Of 71 finished, 54 (76%) have results posted.
Among the 80 studies in Arthritis, Rheumatoid by AbbVie, this one is the 13th largest by enrollment of the 38 interventional ones that give a count, is one of 6 that started in 2010, is one of 4 in phase 4, and was the 19th registered.
AbbVie’s Arthritis, Rheumatoid studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AbbVie’s 80 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX. The study will also evaluate the pharmacokinetics and safety of the two regimens of MTX in combination with ADA in participants with rheumatoid arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).
Biological: Adalimumab · Drug: Methotrexate
Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).
Biological: Adalimumab · Drug: Methotrexate
Adalimumab in pre-filled syringes
Also known as: ABT-D2E7, Humira
Methotrexate capsule
Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24
The DAS28(CRP) score includes 28 tender joint counts, 28 swollen joint counts, C-reactive protein, and participant's global assessment of disease activity. Scores on the DAS28(CRP) range from 0 to 10. A DAS28(CRP) score ≥ 5.1 indicates high disease activity, and a DAS28(CRP) score \< 2.6 indicates clinical remission. Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline DAS28(CRP) value, treatment group, and prior methotrexate dose group.
Time frame: Week 24
Percentage of Participants With Power Doppler Ultrasound (PD U/S) Score for Synovial Vascularity Improvement by 30% at Week 24
PD U/S assessed the severity of synovial inflammation in both hands (bilateral wrists, metacarpophalangeal joints 2, 3, 5, and metatarsophalangeal joint 5). Bilateral images based on dorsal midline imaging of the wrist, dorsal and volar imaging of metacarpophalangeal joints, and dorsal imaging alone of metatarsophalangeal joints are scored using a 4-grade scale: grade 0 or normal = normal joint (no Doppler signal); grade 1 or mild = mild synovitis (≤ 3 isolated signals); grade 2 or moderate = moderate synovitis (\> 3 isolated signals or a confluent signal in \< 50% of synovial area); grade 3 or marked = marked synovitis (signals in ≥ 50% of the synovial area). Each image is rated 0 to 3, for a total possible score ranging from 0 to 48 (16\*0, 16\*3) for 2 hands. Higher grade/score=more severe disease. Change = week 24 score - baseline score.
Time frame: Baseline, 24 weeks
Percentage of Participants With American College of Rheumatology 50% (ACR50) Criteria Response at Week 24
Response, as defined by ACR50 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein).
Time frame: Baseline, 24 weeks
Percentage of Participants With American College of Rheumatology 70% (ACR70) Criteria Response at Week 24
Response, as defined by ACR70 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein).
Time frame: Baseline, 24 weeks
Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤ -0.22 at Week 24
The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (no disability) to 3 (very severe, high dependency disability). The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from baseline of ≤ -0.22. Normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from baseline in the overall score indicates improvement.
Time frame: Baseline, 24 weeks
Percent Change From Baseline in Medical Outcomes Study Version II (MOS) Sleep Problem Index 9 at Week 24
The least squares mean percentage change in MOS Sleep Problem Index 9 from baseline to week 24. The MOS Sleep Problem Index 9 consists of 9 questions to assess sleep, including how long it takes the participant to fall asleep (1=0 to 15 minutes, to 5=more than 60 minutes); and aspects of related to quality of sleep, including how often the participant felt that the sleep was not quiet, felt rested upon waking, awakened short of breath or with a headache, felt drowsy during the day, had trouble falling sleep, how often were awaken, had trouble staying awake during the day, and got needed amount of sleep (1=all the time; 5=none of the time). Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline MOS Sleep Problem Index value, treatment group, and prior methotrexate dose group.
Time frame: Baseline, 24 weeks
Serum Adalimumab Trough Concentrations at Week 24
Serum trough concentrations of adalimumab assessed at week 24 (24 weeks after the 1st dose).
Time frame: Week 24
| Milestone | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| Started | 154 | 155 |
| Completed | 135 | 139 |
| Not completed | 19 | 16 |
| Withdrew: Adverse event | 7 | 6 |
| Withdrew: Withdrawal by subject | 6 | 4 |
| Withdrew: Lost to follow-up | 2 | 5 |
| Withdrew: Lack of efficacy | 2 | 0 |
| Withdrew: Investigator discretion | 1 | 0 |
| Withdrew: Did not meet inclusion criteria | 1 | 0 |
| Withdrew: Noncompliance | 0 | 1 |
The DAS28(CRP) score includes 28 tender joint counts, 28 swollen joint counts, C-reactive protein, and participant's global assessment of disease activity. Scores on the DAS28(CRP) range from 0 to 10. A DAS28(CRP) score ≥ 5.1 indicates high disease activity, and a DAS28(CRP) score \< 2.6 indicates clinical remission. Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline DAS28(CRP) value, treatment group, and prior methotrexate dose group.
| scores on a scale | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24 | 4.11 (3.88 to 4.34) | 3.75 (3.52 to 3.97) |
PD U/S assessed the severity of synovial inflammation in both hands (bilateral wrists, metacarpophalangeal joints 2, 3, 5, and metatarsophalangeal joint 5). Bilateral images based on dorsal midline imaging of the wrist, dorsal and volar imaging of metacarpophalangeal joints, and dorsal imaging alone of metatarsophalangeal joints are scored using a 4-grade scale: grade 0 or normal = normal joint (no Doppler signal); grade 1 or mild = mild synovitis (≤ 3 isolated signals); grade 2 or moderate = moderate synovitis (\> 3 isolated signals or a confluent signal in \< 50% of synovial area); grade 3 or marked = marked synovitis (signals in ≥ 50% of the synovial area). Each image is rated 0 to 3, for a total possible score ranging from 0 to 48 (16\*0, 16\*3) for 2 hands. Higher grade/score=more severe disease. Change = week 24 score - baseline score.
| percentage of participants | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| Percentage of Participants With Power Doppler Ultrasound (PD U/S) Score for Synovial Vascularity Improvement by 30% at Week 24 | 45.45 | 52.38 |
Response, as defined by ACR50 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein).
| percentage of participants | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| Percentage of Participants With American College of Rheumatology 50% (ACR50) Criteria Response at Week 24 | 29.80 | 37.66 |
Response, as defined by ACR70 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein).
| percentage of participants | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| Percentage of Participants With American College of Rheumatology 70% (ACR70) Criteria Response at Week 24 | 13.25 | 20.13 |
The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (no disability) to 3 (very severe, high dependency disability). The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from baseline of ≤ -0.22. Normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from baseline in the overall score indicates improvement.
| percentage of participants | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤ -0.22 at Week 24 | 63.58 | 65.58 |
The least squares mean percentage change in MOS Sleep Problem Index 9 from baseline to week 24. The MOS Sleep Problem Index 9 consists of 9 questions to assess sleep, including how long it takes the participant to fall asleep (1=0 to 15 minutes, to 5=more than 60 minutes); and aspects of related to quality of sleep, including how often the participant felt that the sleep was not quiet, felt rested upon waking, awakened short of breath or with a headache, felt drowsy during the day, had trouble falling sleep, how often were awaken, had trouble staying awake during the day, and got needed amount of sleep (1=all the time; 5=none of the time). Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline MOS Sleep Problem Index value, treatment group, and prior methotrexate dose group.
| percent change | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| Percent Change From Baseline in Medical Outcomes Study Version II (MOS) Sleep Problem Index 9 at Week 24 | -15.42 (-25.36 to -5.49) | -17.27 (-27.95 to -7.58) |
Serum trough concentrations of adalimumab assessed at week 24 (24 weeks after the 1st dose).
| µg/mL | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| Serum Adalimumab Trough Concentrations at Week 24 | 7.1 ± 6.2 | 8.6 ± 5.2 |
Collected over AEs that occurred from the time of study drug administration until 70 days after last dose (total 34 weeks). SAEs were to be collected from the time that informed consent was obtained until 70 days after last dose (total 41 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Adalimumab + Low Dose Methotrexate | — | 6/154 (3.9%) | 57/154 (37%) |
| Adalimumab + High Dose Methotrexate | — | 11/155 (7.1%) | 48/155 (31%) |
| Event | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 1/154 | 0/155 |
| ACUTE MYOCARDIAL INFARCTIONCardiac disorders | 1/154 | 0/155 |
| COLITIS ISCHAEMICGastrointestinal disorders | 1/154 | 0/155 |
| BILE DUCT CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/154 | 0/155 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 1/154 | 0/155 |
| RAYNAUD'S PHENOMENONVascular disorders | 1/154 | 0/155 |
| COLITISGastrointestinal disorders | 0/154 | 1/155 |
| NON-CARDIAC CHEST PAINGeneral disorders | 0/154 | 1/155 |
| ABSCESS SOFT TISSUEInfections and infestations | 0/154 | 1/155 |
| CELLULITISInfections and infestations | 0/154 | 1/155 |
| Event | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate |
|---|---|---|
| NAUSEAGastrointestinal disorders | 15/154 | 16/155 |
| FATIGUEGeneral disorders | 14/154 | 4/155 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 14/154 | 12/155 |
| ALOPECIASkin and subcutaneous tissue disorders | 11/154 | 4/155 |
| URINARY TRACT INFECTIONInfections and infestations | 8/154 | 11/155 |
| DIZZINESSNervous system disorders | 10/154 | 9/155 |
| HEADACHENervous system disorders | 10/154 | 9/155 |
| DIARRHOEAGastrointestinal disorders | 9/154 | 6/155 |
| RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders | 9/154 | 5/155 |
| Age, Continuous(years) | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate | Total |
|---|---|---|---|
| Mean | 55.1 ± 13.11 | 54.5 ± 11.09 | 54.8 ± 12.12 |
| Sex: Female, Male(Participants) | Adalimumab + Low Dose Methotrexate | Adalimumab + High Dose Methotrexate | Total |
|---|---|---|---|
| Female | 120 | 111 | 231 |
| Male | 34 | 44 | 78 |
The record gives a start of Sep 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Adalimumab · Methotrexate
AbbVie (prior sponsor, Abbott) →